BMO Capital Markets started coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report report published on Thursday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $45.00 price target on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on AGIO. Royal Bank of Canada set a $89.00 target price on shares of Agios Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 2nd. Zacks Investment Research raised shares of Agios Pharmaceuticals from a sell rating to a hold rating and set a $46.00 target price on the stock in a report on Wednesday, August 14th. BidaskClub cut shares of Agios Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, September 6th. Goldman Sachs Group reissued a neutral rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. Finally, Cowen reissued a buy rating on shares of Agios Pharmaceuticals in a report on Friday, May 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of Hold and an average price target of $68.57.
Shares of NASDAQ:AGIO opened at $37.74 on Thursday. Agios Pharmaceuticals has a 1-year low of $33.17 and a 1-year high of $79.17. The company’s fifty day moving average is $40.70 and its two-hundred day moving average is $51.34. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.96 and a quick ratio of 5.91.
Several institutional investors have recently added to or reduced their stakes in AGIO. BlackRock Inc. grew its position in shares of Agios Pharmaceuticals by 30.8% during the second quarter. BlackRock Inc. now owns 4,362,184 shares of the biopharmaceutical company’s stock worth $217,585,000 after acquiring an additional 1,027,819 shares during the last quarter. Invesco Ltd. grew its position in shares of Agios Pharmaceuticals by 66.3% during the second quarter. Invesco Ltd. now owns 1,396,773 shares of the biopharmaceutical company’s stock worth $69,671,000 after acquiring an additional 556,825 shares during the last quarter. First Trust Advisors LP grew its position in shares of Agios Pharmaceuticals by 31.4% during the first quarter. First Trust Advisors LP now owns 1,774,158 shares of the biopharmaceutical company’s stock worth $119,649,000 after acquiring an additional 423,931 shares during the last quarter. Westfield Capital Management Co. LP bought a new position in shares of Agios Pharmaceuticals during the first quarter worth about $23,110,000. Finally, First Light Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $12,365,000.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Featured Article: How prevalent are 12b-1 fees?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.